Colorectal cancer represents 8.3 percent of all new cancer diagnoses in the U.S. In 2016, there were an estimated 1,324,922 people in the U.S. living with colorectal cancer. It is the second-leading cause of cancer death in the U.S., accounting for 8.4 percent of all cancer deaths.
The rate of new colorectal cancer cases has been falling an average of 2.4 percent each year over the last 10 years. Death rates fell an average of 2.2 percent each year between 2007 and 2016. Depending on whether and how much the cancer has spread, colorectal cancer is most often treated with radiation, chemotherapy, or surgery.
Source: NIH National Cancer Institute, Cancer Stat Facts: Colorectal Cancer
To support quality improvement (QI) projects in mCRC (metastatic colorectal cancer), the Association of Community Cancer Centers (ACCC) has partnered with Pfizer Global Medical Grants to award $1.5 million in funding for QI projects that are aimed at improving the integration of biomarker testing in personalized treatment selection for patients with mCRC.
The goal of this initiative is to provide guidance for multidisciplinary care teams on how to develop practical biomarker testing protocols for metastatic colorectal cancer and how this information can support personalized treatment decisions for improved patient outcomes.
Association of Community Cancer Centers and Pfizer Award $600,000 in Funding for Quality Improvement in Integration of Biomarker Testing into Personalized Treatment Selection for Colorectal Cancer
Oct 25, 2021